BUZZ-Crinetics soars after Vertex agrees to buy drugmaker in $10 billion deal

CRINETICS PHARMACEUTICALS, INC.
Vertex Pharmaceuticals Incorporated

CRINETICS PHARMACEUTICALS, INC.

CRNX

0.00

Vertex Pharmaceuticals Incorporated

VRTX

0.00

** Shares of Crinetics Pharmaceuticals CRNX.O more than double to $84.69 in extended trading

** Vertex Pharmaceuticals VRTX.O has agreed to acquire CRNX for $85.00 per share in cash for a total equity value of about $10 billion

** Shares of Vertex down 2.8% at $514.75 in extended trading

** The transaction was unanimously approved by both the companies' boards of directors and is anticipated to close in Q3 2026

** Up to last close, CRNX down ~10%, while VRTX up ~17% this year


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.